دورية أكاديمية
Effects of once-weekly semaglutide on coronary outcomes in patients with type 2 diabetes mellitus with or at high risk for cardiovascular disease: insights from the SUSTAIN-6 trial
| العنوان: | Effects of once-weekly semaglutide on coronary outcomes in patients with type 2 diabetes mellitus with or at high risk for cardiovascular disease: insights from the SUSTAIN-6 trial |
|---|---|
| المؤلفون: | Kolkailah, A, Aharonovich, A, Lingvay, I, Dobrecky-Mery, I, Rasmussen, S, Tetens Hoff, S, Mcguire, DK |
| المصدر: | European Journal of Preventive Cardiology ; volume 29, issue Supplement_1 ; ISSN 2047-4873 2047-4881 |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Cardiology and Cardiovascular Medicine, Epidemiology |
| الوصف: | Funding Acknowledgements Type of funding sources: Private company. Main funding source(s): Nordisk A/S Background/introduction In the randomised, double-blind, placebo-controlled SUSTAIN-6 cardiovascular (CV) outcomes trial, once-weekly (OW) semaglutide (a glucagon-like peptide-1 receptor agonist), compared with placebo, reduced the risk of major adverse CV events (CV death, non-fatal myocardial infarction [MI], or non-fatal stroke) and the risk for revascularisation (pre-specified secondary outcome) in patients with type 2 diabetes mellitus (T2DM) with or at high risk for CV disease (CVD). However, the effects of OW semaglutide on composite coronary-specific outcomes have not been explored. Purpose The aim of these post-hoc, exploratory analyses was to assess the effects of OW semaglutide, compared with placebo, on composite coronary outcomes in the SUSTAIN-6 trial population. Methods In these post-hoc analyses of the SUSTAIN-6 trial, the following coronary outcomes were assessed with OW semaglutide (0.5 and 1.0 mg doses pooled) vs placebo, both in addition to standard of care: the main coronary outcome (composite of MI [both fatal and non-fatal] or coronary revascularisation [defined as coronary artery bypass graft surgery or percutaneous coronary intervention]); and the expanded coronary outcome (composite of MI, coronary revascularisation, or unstable angina). Coronary outcomes were assessed overall, as well as in subgroups with or without a prior coronary event (MI or coronary revascularisation) at baseline. Cox proportional hazards regression models were used to analyse time to first event for the outcomes. Results Overall, 3,297 patients were included in these analyses. Key cohort characteristics included a mean age of 64.6 ± 7.4 years with an average T2DM duration of 13.9 ± 8.1 years; 39.3% were female and 48.3% had prior MI or coronary revascularisation (32.5% and 40.3% for each prior event, respectively). The median follow-up duration was 2.1 years. The proportion of patients experiencing a ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1093/eurjpc/zwac056.042 |
| الإتاحة: | https://doi.org/10.1093/eurjpc/zwac056.042Test https://academic.oup.com/eurjpc/article-pdf/29/Supplement_1/zwac056.042/43681394/zwac056.042.pdfTest |
| حقوق: | https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_modelTest |
| رقم الانضمام: | edsbas.E22FF51D |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/eurjpc/zwac056.042 |
|---|